ALBEMARLE (ALB) Company Report

Albemarle entered a cesium concentrate offtake and prepayment agreement of up to C$5 million with Power Metals to advance its 2026 production target at the Case Lake project.
Case Lake hosts a maiden 13,000 t inferred cesium resource at 2.4% Cs₂O, plus an exploration target of 11,000–15,000 t, and requires <C$8 million in capital.
Lithium Royalty Corp. holds a 2.0% gross overriding royalty on Case Lake, positioning it for potential near-term cesium revenue.
Cesium carbonate prices stand at ~US$219,000/t, emphasizing the strategic value of new supply.

Dec 12, 2025, 8:18 PM

Press Release

Albemarle: Global Lithium Hydroxide Market Set to Reach USD 92.19 Billion by 2033

ALB

Product Launch

Global lithium hydroxide market projected to grow from USD 28.87 B in 2025 to USD 92.19 B by 2033 at a 15.62% CAGR (2026–2033)
U.S. lithium hydroxide market estimated at USD 4.71 B in 2025E and forecast to reach USD 13.28 B by 2033 at a 14.05% CAGR
In 2025, hard rock source held 54.37% share; battery-grade accounted for 72.85%; electric vehicles application represented 61.24%; Asia Pacific led regionally with 46.78% share
Albemarle launched an advanced battery-grade lithium hydroxide product line in June 2025 to support next-generation EV batteries

Dec 3, 2025, 12:30 PM

Press Release

Albemarle reports Q3 2025 earnings

ALB

Earnings

Guidance Update

M&A

Albemarle reported Q3 2025 net sales of $1.3 billion, a net loss narrowed to $161 million (Q3 2024: $1.07 billion), Adj. EBITDA of $226 million, and an adjusted loss per share of $0.19.
Operational execution delivered volume growth in Energy Storage and Ketjen of +8% each, with cost and efficiency improvements offsetting lower lithium pricing.
Cash from operations was $356 million in Q3 (up 57% Y/Y) and $894 million YTD (up 29% Y/Y), yielding net debt to adjusted EBITDA of 2.1x.
The company expects FY 2025 free cash flow of $300–400 million, with capital expenditures reduced to ~$600 million, and enterprise results tracking toward the higher end of the $9/kg LCE scenario.
Albemarle agreed to sell a 51% stake in its Ketjen refining catalyst business and its interest in the Eurecat JV for combined pre-tax proceeds of ~$660 million, closing in H1 2026.

Nov 6, 2025, 1:00 PM

Presentation

Albemarle reports Q3 2025 results

ALB

Earnings

Guidance Update

Albemarle's Q3 net sales were $1.3 billion, adjusted EBITDA was $226 million (+7% yoy), with a net loss of $1.72 per diluted share and an adjusted diluted loss of $0.19 per share.
Year-to-date through Q3, EBITDA-to-operating cash flow conversion exceeded 100%; full-year cash conversion is expected to exceed 80%, and free cash flow is projected at $300 million–$400 million.
The company closed Q3 with $1.9 billion in cash, plans to repay its maturing Eurobond, expects modestly negative free cash flow in Q4, and anticipates ~$660 million of gross proceeds from Ketjen transactions in 2026, leaving ~$1.4 billion available for deployment.
Full-year 2025 results are forecast near the upper end of the $9/kg lithium price scenario; Q4 energy storage EBITDA is expected to be slightly higher sequentially, specialties EBITDA lower, and Ketjen EBITDA stronger.

Nov 6, 2025, 1:00 PM

Transcript

Albemarle reports Q3 2025 results and updates 2025 outlook

ALB

Earnings

Guidance Update

M&A

Albemarle reported Q3 net sales of $1.3 billion, adjusted EBITDA of $226 million (↑7% YoY), and $356 million in operating cash (↑57% YoY).
Company now anticipates full-year 2025 results toward the upper end of its $9/kg lithium price scenario, projects $300–$400 million in free cash flow, $600 million in CapEx, and $450 million in cost/productivity improvements.
Announced definitive agreements to sell a 51% stake in Ketjen’s refining catalyst business and exit the Eurocat JV, expected to close H1 2026 and generate $660 million in pre-tax proceeds.
Demand for lithium remains robust, with >30% YTD growth in global lithium consumption, 30% increase in EV sales, and 105% surge in grid storage installations.

Nov 6, 2025, 1:00 PM

Transcript

Albemarle reports Q3 2025 earnings and outlook

ALB

Earnings

Guidance Update

M&A

In Q3, Albemarle posted net sales of $1.3 billion and adjusted EBITDA of $226 million (+7% YoY); reported net loss of $1.72 per share and adjusted loss per share of $0.19.
Generated $356 million in cash from operations (up 57% YoY) and achieved >100% YTD EBITDA-to-cash conversion, supporting full-year free cash flow guidance of $300–$400 million.
Delivered $450 million in cost and productivity improvements (exceeding the initial $300–$400 million target) and cut 2025 CapEx to $600 million (65% reduction YoY).
Updated 2025 outlook toward the upper end of the $9 per kg lithium price scenario, with average lithium pricing expected at $9.50/kg, amid 30% YTD EV sales growth and 105% YTD grid storage growth.
Announced sales of a 51% stake in Ketjen’s refining catalyst business and Ketjen’s Eurocat JV interest, expected to close in H1 2026 and generate ~$660 million in pre-tax proceeds.

Nov 6, 2025, 1:00 PM

Transcript

Albemarle reports Q3 2025 earnings and updates outlook

ALB

Earnings

Guidance Update

Reported $1.3 billion in net sales, $226 million in adjusted EBITDA (up 7%), and a net loss of $161 million (or $1.72 per diluted share); adjusted loss was $0.19 per share.
On track for $450 million in full-year cost and productivity savings, reduced 2025 capital expenditures to $600 million, and expects $300–$400 million in free cash flow.
Generated $356 million of operating cash flow in Q3 (up 57%) and $894 million year-to-date (up 29%).
Enhanced full-year outlook toward the higher end of the $9/kg lithium price scenario and agreed to sell stakes in Ketjen and the Eurecat JV for $660 million of pre-tax proceeds.

Nov 5, 2025, 9:20 PM

8-K

Albemarle reports Q3 2025 results

ALB

Earnings

Guidance Update

M&A

Net sales of $1.3 billion (down 3% YoY) and adjusted EBITDA of $226 million (up 7% YoY); net loss of $161 million, or $1.72 per diluted share (adjusted loss of $0.19 per share).
Third quarter cash from operations of $356 million (up 57% YoY) and year-to-date cash from operations of $894 million (up 29% YoY), driven by cost savings and a customer prepayment.
Reduced full-year 2025 capital expenditures outlook to $600 million and expect positive free cash flow of $300–400 million; anticipate full-year results toward the higher end of the $9/kg lithium price scenario.
Announced agreements to sell stakes in Ketjen and the Eurecat joint venture for combined pre-tax proceeds of $660 million.

Nov 5, 2025, 9:15 PM

Press Release

Albemarle to sell majority stake in Ketjen and Eurecat interest for $660M

ALB

M&A

Albemarle agreed to sell a 51% stake in its Ketjen refining catalyst business to KPS Capital Partners while retaining 49% ownership and operational control of the Performance Catalyst Solutions unit.
The company will divest its 50% interest in the Eurecat joint venture to Axens SA in a combined transaction valued at $660 million, expected to close in H1 2026.
The sale will generate $536 million in cash proceeds for debt reduction and corporate purposes, alongside a $181.5 million goodwill impairment in the Refining Solutions unit.
Albemarle plans to refocus on its core lithium and bromine businesses and strengthen its financial position amid market uncertainties.

Oct 27, 2025, 11:32 AM

Morningstar

Albemarle to sell controlling stake in Ketjen refining catalyst business

ALB

M&A

KPS Capital Partners will acquire a 51% stake in Albemarle’s Ketjen refining catalyst solutions business, with Albemarle retaining 49%; the transaction is expected to close in Q1 2026.
Ketjen is a global catalyst manufacturer headquartered in Houston with approximately 840 employees, operating two manufacturing sites, two R&D centers, and two joint ventures across the Americas, Europe, and Asia.
Albemarle will maintain 100% ownership of Ketjen’s Performance Catalyst Solutions (PCS) business after the deal closes.
The acquisition is supported by committed debt financing from Barclays, Jefferies, BNP Paribas, and Santander; Paul, Weiss, Rifkind, Wharton & Garrison LLP serves as legal counsel and Raymond James as financial advisor to KPS.

Oct 27, 2025, 11:26 AM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for ALBEMARLE.

Q3 2025

Nov 6, 2025

→

Q2 2025

Jul 31, 2025

→

Q1 2025

May 1, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did J. Kent Masters say about margins?What are ALBEMARLE's strategic priorities?How is ALBEMARLE positioned vs competitors?How did ALBEMARLE do last quarter?

ALBEMARLE (ALB)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

J. Kent Masters

Ander Krupa

Eric Norris

Mark Mummert

Melissa Anderson

Neal Sheorey

Board Members

Alejandro Wolff

Dean Seavers

Diarmuid O'Connell

Gerald Steiner

Glenda Minor

Holly Van Deursen

James O'Brien

Lauren Brlas

Ralf Cramer

Analyst Coverage

Aleksey Yefremov

Joel Jackson

Rock Hoffman Blasko

Vincent Andrews

David Deckelbaum

Laurence Alexander

Arun Viswanathan

David Begleiter

John Ezekiel Roberts

Patrick Cunningham

Jeffrey Zekauskas

Abigail Eberts

Andres Castanos-Mollor

Ben Kallo

Chris Farrell

Christopher Perrella

Colin Rusch

Edlain Rodriguez

Harris Fein

Matthew Hettwer

Apurva Kilambi

Ben Isaacson

Christopher Parkinson

Eric Zhang

Josh Spector

Joshua Spector

Kevin McCarthy

Michael Sison

Peter Osterland

Rachael Lee

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent